Journal of
Nephrology & Renal Diseases

Abstract

New possibilities in the treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD)

Shutov E.V.

Botkin Clinical City Hospital, Russian Medical Academy of Continuous Professional Education, Moscow, Russia

Abstract:

Despite the understanding of the problem of treatment CKD-MBD, success in the treatment of this pathology is very modest. This was primarily due to the absent of effective drugs to achieve target biochemical parameters. Recently, new phosphate binders containing iron and calcimimetics have become available for treatment of CKD-MBD. The aim of the study was to assess the effect of new drugs on CKD-MBD targets, including FGF-23, Klotho, PTH, P, Ca and others. We got a good effect from the use of a combination of calcimimetics and phosphate binders containing iron. Only an assessment of the changes in all disease markers under the influence of new drugs gave us the opportunity to improve approaches to treating CKD-MBD.

Conclusions: Based on our own research results, we can conclude that in the treatment of CKD -MBD we must use new highly effective drugs to achieve the target parameters, including FGF 23 and Klotho.

Biography:

Prof. Shutov E.V. is working many years on the problem of treating patients with ⃞KD. He heads the largest nephrology center in Russia, where there are excellent results in clinical outcomes (dialysis patients mortality 6-7% per year). He uses his own algorithms for treating complications in these patients (anemia, CKD -MBD, infections, hydration, cardiovascular disease).

Recent Publications:

1. Marinella Ruospo, Suetonia C Palmer, Patrizia Natale, Jonathan C Craig, Mariacristina Vecchio, Grahame J Elder, and Giovanni FM Strippoli .Phosphate binders for preventing and treating chronic kidney disease⃞mineral and bone disorder (CKD⃞MBD) Cochrane Database Syst Rev. 2018 Aug; 2018(8)

2. Jordi Bover, *† Pablo Ureña,‡§ César Ruiz-García,*† Iara daSilva,*† Patricia Lescano,*† Jacqueline del Carpio,*† José Ballarín,*† and Mario Cozzolino Clinical and Practical Use of Calcimimetics in Dialysis Patients With Secondary Hyperparathyroidism . Clin J Am Soc Nephrol. 2016 Jan 7; 11(1): 161–174.

3. Keith E Eidman1 and James B Wetmore 1, Managing hyperparathyroidism in hemodialysis: role of etelcalcetide Int J Nephrol Renovasc Dis. 2018; 11: 69–80.

4. Claudia Friedl1 and Emanuel Zitt2 Role of etelcalcetide in the management of secondary hyperparathyroidism in hemodialysis patients: a review on current data and place in therapy. Drug Des Devel Ther. 2018; 12: 1589–1598

5. Makoto Kuro-o A phosphate-centric paradigm for pathophysiology and therapy of chronic kidney disease. Kidney Int Suppl (2011). 2013 Dec; 3(5): 420–426.

6. Hisato Shima, Keiko Miya, Kazuyoshi Okada, Jun Minakuchi, and Shu Kawashima

7. Sucroferric oxyhydroxide decreases serum phosphorus level and fibroblast growth factor 23 and improves renal anemia in hemodialysis patients. BMC Res Notes, 201811: 363

8th International Conference on Nephrology and Urology; April 24-25, 2020; Prague, Czech Republic

Citation: Shutov E.V.; New possibilities in the treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD); April 24-25, 2020; Prague, Czech Republic